Gataparsen

Gataparsen
Clinical data
Other namesLY2181308
Legal status
Legal status
  • Investigational
Identifiers
CAS Number
UNII

Gataparsen (development code LY2181308) is an antisense oligonucleotide that complementarily binds to survivin mRNA and inhibits its expression in tumor tissue.[1]

It being investigated for a number of different cancers.[2]

It is targeted at survivin which prevents cells dying.[3]

Clinical trials

It has completed a phase II trial for acute myeloid leukemia.[4]

A phase II trial for non-small cell lung cancer has started.[5]

A phase II trial for hormone-refractory prostate cancer will run until early 2012.[6]

References

  1. ^ Tanioka M, Nokihara H, Yamamoto N, Yamada Y, Yamada K, Goto Y, et al. (August 2011). "Phase I study of LY2181308, an antisense oligonucleotide against survivin, in patients with advanced solid tumors". Cancer Chemotherapy and Pharmacology. 68 (2): 505–11. doi:10.1007/s00280-010-1506-7. PMID 21079959.
  2. ^ "Search of: LY2181308". ClinicalTrials.gov.
  3. ^ "Cancer". Isis Pharmaceuticals. Archived from the original on 2009-10-10. Retrieved 2019-08-31.
  4. ^ "A Study of LY2181308 Sodium in Patients With Relapsed or Refractory Acute Myeloid Leukemia". ClinicalTrials.gov.
  5. ^ "Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer". ClinicalTrials.gov.
  6. ^ "A Study of an Experimental Chemotherapy Combination to Treat Hormone Refractory Prostate Cancer". ClinicalTrials.gov.
Stub icon

This antineoplastic or immunomodulatory drug article is a stub. You can help Wikipedia by expanding it.